Skip to main content

Advertisement

SpringerLink
Log in

CD 152 gene polymorphisms and risk of osteosarcoma in Chinese population

  • Research Article
  • Published:
Tumor Biology

Abstract

Osteosarcoma has become a health threat for adolescents and young adults. To identify the genetic risk factor for the malignancy is in urgent need. Several studies have investigated the role of CD 152 polymorphisms in osteosarcoma in a sample of Chinese population. However, the association is poorly defined due to lack of a sufficiently large sample. In this study, we performed a meta-analysis of all CD 152 polymorphisms that had been implicated in osteosarcoma to examine the association. We searched the electronic MEDLINE database until December 31, 2013, to identify the studies regarding the association between CD 152 polymorphisms and osteosarcoma. Inclusion criteria were followed in the selection of eligible study. The genotypic and allelic data were collected from all studies included to evaluate the risk of osteosarcoma (odds ratio, OR). We found statistically significant evidence of the studied CD 152 polymorphisms and increased risk of osteosarcoma in homozygous (OR = 1.79, 95 % CI = 1.40–2.29, P = 0.958), recessive (OR = 1.77, 95 % CI = 1.40–2.25, P = 0.899), and allele model (OR = 1.21, 95 % CI = 1.09–1.34, P = 1.000). This increased risk was also revealed in single nucleotide polymorphism (SNP) +49G>A and SNP 326G>A. Our meta-analysis indicates that there may be an association between CD 152 polymorphisms and risk of osteosarcoma in Chinese population. Further validation of the observation is necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–8.

    Google Scholar 

  2. Kämmerer PW, Toyoshima T, Schöder F, Kämmerer P, Kuhr K, Brieger J, et al. Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma. Oral Oncol. 2010;46(7):543–8.

    Google Scholar 

  3. Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M, et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol. 2007;68(8):698–704.

    Google Scholar 

  4. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–48.

    Article  PubMed  Google Scholar 

  5. Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev. 2006;212:131–48.

    Article  CAS  PubMed  Google Scholar 

  6. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100(14):8372–7.

    Google Scholar 

  7. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005;175(11):7746–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100(8):4712–7.

    Google Scholar 

  9. Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Ries LAG, Smith MA, Gurney JG, editors. Cancer incidence and survival among children and adolescents. Bethesda: National Cancer Institute; 1999. p. 99–110. NIH Pub. No. 99–4649.

    Google Scholar 

  10. Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75(1 Suppl):203–10.

    Article  CAS  PubMed  Google Scholar 

  11. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–43.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 2011;30(12):1051–5.

    Google Scholar 

  13. Wang W, Wang J, Song H, Liu J, Song B, Cao X. Cytotoxic T-lymphocyte antigen-4 + 49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers. 2011;15(7–8):503–6.

    Google Scholar 

  14. He J, Wang J, Wang D, Dai S, Yv T, Chen P, et al. Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population. Endocrine. 2014;45(2):325–30.

    Google Scholar 

  15. Yu F, Miao J. Significant association between cytotoxic T lymphocyte antigen 4 + 49G > A polymorphism and risk of malignant bone tumors. Tumour Biol. 2013;34(6):3371–5.

    Article  CAS  PubMed  Google Scholar 

  16. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.

    CAS  PubMed  Google Scholar 

  17. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.

    Article  Google Scholar 

  18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    Article  PubMed  Google Scholar 

  19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

    Article  CAS  PubMed  Google Scholar 

  20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.

    Article  CAS  PubMed  Google Scholar 

  21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

    Google Scholar 

  22. Yang S, Wang C, Zhou Y, Sun G, Zhu D, Gao S. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to Ewing's sarcoma. Genet Test Mol Biomarkers. 2012;16(10):1236–40.

    Google Scholar 

  23. Feng D, Yang X, Li S, Liu T, Wu Z, Song Y, et al. Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma. Genet Test Mol Biomarkers. 2013;17(6):458–63.

    Google Scholar 

  24. Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A, et al. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet. 2006;165(2):114–20.

    Google Scholar 

  25. Jaiswal PK, Singh V, Mittal RD. Cytotoxic T lymphocyte antigen 4 (CTLA4) gene polymorphism with bladder cancer risk in North Indian population. Mol Biol Rep. 2014;41(2):799–807.

    Article  CAS  PubMed  Google Scholar 

  26. Qiu H, Tang W, Yin P, Cheng F, Wang L. Cytotoxic T-lymphocyte-associated antigen-4 polymorphisms and susceptibility to cervical cancer: a meta-analysis. Mol Med Rep. 2013;8(6):1785–94.

    Google Scholar 

  27. Harper K, Balzano C, Rouvier E, Mattéi MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol. 1991;147(3):1037–44.

    Google Scholar 

  28. Seder RA, Germain RN, Linsley PS, Paul WE. CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production. J Exp Med. 1994;179(1):299–304.

    Google Scholar 

  29. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. Pillars article: CTLA-4 can function as a negative regulator of T cell activation. J Immunol. 2011;187(7):3466–74.

    Google Scholar 

  30. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol. 1999;162(10):5813–20.

    Google Scholar 

  31. Bai XF, Liu J, May KF Jr, Guo Y, Zheng P, Liu Y. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo. Blood. 2002;99(8):2880–9.

    Google Scholar 

  32. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedics, General Hospital of Jinan Military Commanding Region, Jinan, 250031, Shandong Province, China

    Zhengqi Chang, Ruoxian Song, Songfeng Xu, Ming Xu & Xiuchun Yu

Authors
  1. Zhengqi Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruoxian Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Songfeng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ming Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiuchun Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiuchun Yu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, Z., Song, R., Xu, S. et al. CD 152 gene polymorphisms and risk of osteosarcoma in Chinese population. Tumor Biol. 35, 6809–6814 (2014). https://doi.org/10.1007/s13277-014-1891-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1891-3

Keywords

Search

Navigation